Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
(firmenpresse) - MONMOUTH JUNCTION, NJ -- (Marketwired) -- 09/12/13 -- CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as , is a proud sponsor of both the and the event hosted by the tonight in New York City, in honor of the second annual tomorrow.
The Global Sepsis Alliance estimates that . Sepsis is the end result of an overzealous immune response to a severe infection. Without effective therapies and with delayed diagnosis, sepsis claims more than 8 million deaths each year, killing patients of all ages, races, ethnicities, religions, and socio-economic backgrounds despite the widespread use of antibiotics.
"CytoSorbents is dedicated to developing new therapies to treat sepsis. Our European Union-approved blood filter, CytoSorb®, targets the prevention or treatment of organ failure -- the leading cause of death in sepsis," stated Dr. Phillip Chan, CEO of CytoSorbents. "Unlike any other therapy before it, CytoSorb® attacks sepsis from many different angles. It works to control the wayward inflammatory response that can lead to organ failure and more infection. It can also remove many deadly bacterial toxins. And it helps direct the activated immune system to the site of infection, and away from healthy organs where it can cause damage, as seen in animal studies. No other therapy has demonstrated this broad spectrum approach to treating sepsis and CytoSorb® is available now to critically ill patients in Europe."
In the past two weeks, CytoSorbents has engaged in multiple events surrounding World Sepsis Day.
Exhibited at the in Weimar, Germany, sponsored by the , where two clinical case report posters and a research poster were accepted for presentation, by researchers from hospitals in Linz - Austria, Ulm - Germany, and Jena - Germany. The Linz case report was selected for an oral presentation and highlighted the successful use of CytoSorb® with hemodialysis in a dying 36 year old woman with end stage liver failure with catastrophic failure of her major organs due septic shock from a severe bacterial pneumonia. Despite more than a 90% risk of dying, she stabilized with treatment and recovered. The clinical case report from Ulm detailed another successful use of CytoSorb® in a highly unstable 46 year old woman with septic shock from a serious yeast blood infection. She went on to recover as well.
Sponsored and participated in the in Berlin, Germany on September 9, 2013 held by the German Federal Minister of Health
Sponsored the in New York City, which will take place tonight at the Arena NYC from 7:30-9:00PM EDT, celebrating champions of sepsis awareness, including New York State Governor Andrew M. Cuomo and many others
"Given our significant focus on sepsis, we are proud to be active supporters of these worthy organizations and World Sepsis Day," stated Dr. Chan.
World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding non-profit members: The World Federation of Societies of Intensive and Critical Care Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, the World Federation of Critical Care Nurses, the International Sepsis Forum, and the Sepsis Alliance. The goals of World Sepsis Day are to:
Reduce the incidence of sepsis through effective prevention strategies
Increase sepsis survival rates for all population groups around the world
Provide better access to suitable rehabilitation services for people everywhere
Increase awareness and understanding of sepsis among healthcare professionals and the general public
For more information, visit
The Global Sepsis Alliance (GSA) is a non-profit organization supporting the efforts of over 1 million caregivers in more than 70 countries as they seek to better understand and combat what many experts believe to be the leading cause of death worldwide: sepsis. The GSA has rallied the Global Sepsis Community to elevate public, philanthropic and governmental awareness, understanding and support of sepsis and to accelerate collaboration among researchers, clinicians, associated working groups and those dedicated to supporting them. For more information, visit
The German Sepsis Society (GSS) is the primary medical society in Germany whose mission is to educate and increase public and professional awareness about sepsis. The organization brings together leaders in sepsis research, diagnostics, treatment, and education in order to also encourage new research, recognize valuable scientific contributions, and foster collaborations to help save lives. A major goal is to support the rapid implementation of effective sepsis diagnostics and therapies into the standard of care treatment for sepsis. Members of the GSS have been heavily involved with SepNet, or the Sepsis Competence Network, a consortium of hospitals and investigators funded for 10 years by the German Federal Ministry of Education to conduct research and clinical trials in sepsis. The GSS also initiated the foundation of the organization, German Sepsis Aid, by people who survived sepsis and their relatives, to provide assistance, information, and networking for those whose lives have been touched by sepsis. For more information, visit
The Sepsis Alliance is a charitable organization run by a team of dedicated laypeople and professionals who share a strong commitment to battling sepsis. The goal is to raise awareness of sepsis through information and educational material so it can be detected and treated early enough that no harm is done. The Sepsis Heroes Evening is an award reception, being held on World Sepsis Day in New York City, designed to raise awareness of sepsis and to recognize the unique contributions of individuals who have committed their time and energy for the cause. For more information, visit
CytoSorbents is a critical care focused therapeutic device company using blood purification to modulate the immune system - with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website:
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on April 3, 2013, which is available at .
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
Valter Pinto
(914) 669-0222 x201
JQA Partners
Jules Abraham
(917) 885-7378
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.09.2013 - 04:00 Uhr
Sprache: Deutsch
News-ID 1262793
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONMOUTH JUNCTION, NJ
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
"
steht unter der journalistisch-redaktionellen Verantwortung von
CytoSorbents Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
